FDA Approves RILPIVIRINE — Somerset Therapeutics, LLC

# FDA Approves Somerset Therapeutics' Generic Rilpivirine Somerset Therapeutics, LLC has received FDA approval for its generic rilpivirine hydrochloride oral formulation (ANDA218798), expanding treatment options in the competitive HIV market and potentially increasing price competition for this non-nucleoside reverse transcriptase inhibitor. The approval could drive down costs for patients and payers while enabling Somerset to capture market share in a therapeutic category where branded and generic alternatives already exist.